{"organizations": [], "uuid": "74ae1ee11cfcfcaadde0c3eca7dd0a9b95c289b6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "uk.reuters.com", "main_image": "https://s1.reutersmedia.net/resources/r/?m=02&d=20180503&t=2&i=1258015857&w=1200&r=LYNXMPEE420HA", "site_section": "http://feeds.reuters.com/reuters/UKHealthNews/", "section_title": "Reuters: Health News", "url": "https://uk.reuters.com/article/uk-merck-merkel-family/merck-kgaa-family-says-unreservedly-behind-the-pharma-unit-idUKKBN1I40TZ", "country": "US", "domain_rank": 408, "title": "Merck KGaA family says unreservedly behind the pharma unit", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-03T11:56:00.000+03:00", "replies_count": 0, "uuid": "74ae1ee11cfcfcaadde0c3eca7dd0a9b95c289b6"}, "author": "", "url": "https://uk.reuters.com/article/uk-merck-merkel-family/merck-kgaa-family-says-unreservedly-behind-the-pharma-unit-idUKKBN1I40TZ", "ord_in_thread": 0, "title": "Merck KGaA family says unreservedly behind the pharma unit", "locations": [], "entities": {"persons": [{"name": "patricia weiss", "sentiment": "none"}, {"name": "frank stangenberg-haverkamp", "sentiment": "none"}, {"name": "maria sheahan", "sentiment": "none"}], "locations": [{"name": "darmstadt", "sentiment": "none"}, {"name": "darmstadt", "sentiment": "none"}, {"name": "germany", "sentiment": "none"}], "organizations": [{"name": "merck kgaa", "sentiment": "negative"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "ludwig burger", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 3, 2018 / 9:07 AM / a few seconds ago Merck KGaA family says unreservedly behind the pharma unit Reuters Staff 1 Min Read\nDARMSTADT, Germany (Reuters) - The family behind Germany’s Merck KGaA ( MRCG.DE ) said it was fully committed to the group’s pharmaceuticals unit, even if cancer immunotherapy hopeful avelumab does not achieve blockbuster sales. FILE PHOTO: A logo of drugs and chemicals group Merck KGaA is pictured in Darmstadt, Germany January 28, 2016. REUTERS/Ralph Orlowski/File Photo\n“Pharma is one of our three pillars and we absolutely stand behind it. If avelumab doesn’t become a blockbuster there are enough highly interesting products in our pipeline,” said family representative Frank Stangenberg-Haverkamp, speaking at an event marking the group’s 350-year anniversary at its Darmstadt, Germany headquarters. Reporting by Patricia Weiss; Writing by Ludwig Burger; Editing by Maria Sheahan", "external_links": [], "published": "2018-05-03T11:56:00.000+03:00", "crawled": "2018-05-03T12:16:23.002+03:00", "highlightTitle": ""}